Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy

Pharmacotherapy

Volumn 33, Issue 10, 2013, Pages

  Gonzalez, Jaime E ^a   Sauer, William H ^a,b   Krantz, Mori J ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CPC Clinical Research   (United States)

^c DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

Author keywords

Arrhythmia; dronedarone; premature ventricular complex; QT prolongation

Indexed keywords

ATORVASTATIN; DRONEDARONE; FUROSEMIDE; WARFARIN;

AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; CARDIOVERSION; CASE REPORT; CENTRAL VENOUS PRESSURE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ECTOPIA CORDIS; ELECTROCARDIOGRAPHY; FATIGUE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART RATE; HEART SOUND; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MALAISE; MALE; OXYGEN SATURATION; QT PROLONGATION; SYSTOLIC HEART MURMUR;

ARRHYTHMIA; DRONEDARONE; PREMATURE VENTRICULAR COMPLEX; QT PROLONGATION;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY, AMBULATORY; FATIGUE; HUMANS; LONG QT SYNDROME; MALE; VENTRICULAR PREMATURE COMPLEXES;

EID: 84900848610     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1330     Document Type: Article

References (11)

1. Vassallo P, Trohman R,. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298 (11): 1312-22.
2. Poluzzi E, Raschi E, Moretti U, De Ponti F,. Drug induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009; 18 (6): 512-8.
3. Milberg P, Frommeyer G, Uphaus T, et al. Electrophysiologic profile of dronedarone on the ventricular level: Beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization. J Cardiovasc Pharmacol 2012; 59: 92-100.
4. Food and Drug Administration. FDA Product Label, Dronedarone, September 2012. Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index/cfm?fuseaction=Seach.Label-ApprovalHistory#labelinfo. Accessed March 22, 2013.
5. Hondeghem LM, Dujardin K, De Clerck F,. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc Res 2001; 50 (2): 345-53.
6. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15 (2): 475-95.
7. Hohnloser SH, Crijns H, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-78.
8. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired Long-QT syndrome. Circulation 2001; 104: 2722-7.
9. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk atrial fibrillation. N Engl J Med 2011; 365: 2268-76.
10. Kao DP, Hiatt WR, Krantz MJ,. Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. Pharmacotherapy 2012; 32 (8): 767-71.
11. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.